Biogen Inc.
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Biogen Inc.
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $9.9B
Biogen makes money through specialty drug sales, collaboration revenue, royalties, and profit-sharing arrangements. The company focuses on neurologists, rare-disease specialists, specialty pharmacies, payers, and partners in areas where clinical expertise and market access matter.
The growth strategy is portfolio focus: protect cash from mature assets, invest behind selected neuroscience and rare-disease launches, partner where risk sharing helps, and keep operating expenses disciplined.
Biogen makes money from product sales, collaboration revenue, royalties, and profit-sharing arrangements tied to neuroscience, rare disease, immunology, and Alzheimer's programs.
Biogen serves patients, neurologists, hospitals, specialty pharmacies, payers, health systems, and biopharma partners.
The key driver is a portfolio of neurology products and partner programs, with Tysabri, Spinraza, anti-CD20 royalties, and newer launches shaping the revenue mix.
Biogen's durability comes from specialist neurology relationships, regulatory expertise, biologics manufacturing know-how, and a deep clinical-development history.
Biogen's biggest risk is erosion in mature multiple-sclerosis franchises, uncertain uptake for newer neurodegeneration products, reimbursement friction, and pipeline execution risk.